Maryland 2022 Regular Session

Maryland Senate Bill SB189 Compare Versions

Only one version of the bill is available at this time.

Old	New	Differences
1	1
2	2
3	3	EXPLANATION: CAPITALS INDICATE MAT TER ADDED TO EXISTIN G LAW.
4	4	[Brackets] indicate matter deleted from existing law.
5	5	sb0189
6	6
7	7	SENATE BILL 189
8	8	J3 2lr0055
9	9	(PRE–FILED)
10	10	By: Chair, Judicial Proceedings Committee (By Request – Departmental – Health)
11	11	Requested: October 5, 2021
12	12	Introduced and read first time: January 12, 2022
13	13	Assigned to: Judicial Proceedings
14	14
15	15	A BILL ENTITLED
16	16
17	17	AN ACT concerning 1
18	18
19	19	Controlled Substances – Schedules 2
20	20
21	21	FOR the purpose of altering the lists of substances designated as controlled dangerous 3
22	22	substances under certain schedules under the Maryland Controlled Dangerous 4
23	23	Substances Act; and generally relating to schedules for controlled dangerous 5
24	24	substances. 6
25	25
26	26	BY repealing and reenacting, with amendments, 7
27	27	Article – Criminal Law 8
28	28	Section 5–402 through 5–406 9
29	29	Annotated Code of Maryland 10
30	30	(2021 Replacement Volume and 2021 Supplement) 11
31	31
32	32	SECTION 1. BE IT ENACTED BY THE GENERAL ASSEMBLY OF MARYLAND, 12
33	33	That the Laws of Maryland read as follows: 13
34	34
35	35	Article – Criminal Law 14
36	36
37	37	5–402. 15
38	38
39	39	(a) Schedule I consists of each controlled dangerous substance: 16
40	40
41	41	(1) listed in this section; 17
42	42
43	43	(2) added to Schedule I by the Department under § 5–202(b) of this title; or 18
44	44
45	45	(3) designated as a Schedule I controlled dangerous substance by the 19
46	46	federal government unless the Department objects under § 5–202(f) of this title. 20
47	47
48	48	(b) Unless specifically excepted under this subtitle or listed in another schedule, 21 2 SENATE BILL 189
49	49
50	50
51	51	any of the following opiates, including their isomers, including optical and geometric 1
52	52	isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, whenever the 2
53	53	existence of such isomers, esters, ethers, or salts is possible within the specific chemical 3
54	54	designation, are substances listed in Schedule I: 4
55	55
56	56	(1) acetyl–alpha–methylfentanyl (N–[1–(1–methyl–2–phenethyl)–4–5
57	57	piperidinyl]–N–phenylacetamide); 6
58	58
59	59	(2) acetylmethadol; 7
60	60
61	61	(3) acetyl fentanyl (N–(1–phenethylpiperidin–4–yl)–N–phenylacetamide); 8
62	62
63	63	(4) Acryl fentanyl (N–(1–phenethylpiperidin–4–yl)–N–phenylacrylamide; 9
64	64
65	65	(5) AH–7921 (3,4–dichloro–N–[(1–dimethylamino) cyclohexylmethyl]) 10
66	66	benzamide; 11
67	67
68	68	(6) allylprodine; 12
69	69
70	70	(7) alphacetylmethadol, except levo–alphacetylmethadol; 13
71	71
72	72	(8) alphameprodine; 14
73	73
74	74	(9) alphamethadol; 15
75	75
76	76	(10) alpha–methylfentanyl (N –[1–(alpha–methyl–beta–phenyl)ethyl 16
77	77	–4– piperidyl] propionanilide; 1–(1–methyl–2–phenylethyl)–4–(N–propanilido) piperidine); 17
78	78
79	79	(11) alpha–methylthiofentanyl (N –[1–methyl–2–(2–thienyl)ethyl 18
80	80	–4– piperidinyl]–N–phenylpropanamide); 19
81	81
82	82	(12) benzethidine; 20
83	83
84	84	(13) betacetylmethadol; 21
85	85
86	86	(14) beta–hydroxyfentanyl (N –[1–(2–hydroxy–2–phenethyl) 22
87	87	–4–piperidinyl]–N–phenylpropanamide); 23
88	88
89	89	(15) beta–hydroxy–3–methylfentanyl (N–[1–(2–HYDROXY–2–24
90	90	PHENYLETHYL )–3–METHYL–4–PIPERIDINYL]–N–PHENYLPROPANAMIDE ; 25
91	91
92	92	(16) BETA–HYDROXYTHIOFENTANYL (N–[1–[2–hydroxy–2–(thiophen–2–26
93	93	yl)ethyl]piperidin–4–yl]–N–phenylpropionamide); 27
94	94
95	95	(17) betameprodine; 28
96	96
97	97	(18) betamethadol; 29 SENATE BILL 189 3
98	98
99	99
100	100
101	101	(19) BETA–METHYLFENTANYL (N–PHENYL–N–(1–(2 1
102	102	–PHENYLPROPYL )PIPERIDIN–4–YL)PROPIONAMIDE ; ALSO KNOWN AS Β –2
103	103	METHYLFENTANYL ); 3
104	104
105	105	(20) BETA′–PHENYL FENTANYL (N–(1–PHENETHYLPIPERIDIN –4–YL) 4
106	106	–N,3–DIPHENYLPROPANAMIDE ; ALSO KNOWN AS Β ′–PHENYL FENTANYL ; 5
107	107	3–PHENYLPROPANOYL FENT ANYL); 6
108	108
109	109	[(19)] (21) betaprodine; 7
110	110
111	111	[(20)] (22) butyryl fentanyl (N –(1–phenethylpiperidin–4–yl) 8
112	112	–N–phenylbutyramide); 9
113	113
114	114	[(21)] (23) clonitazene; 10
115	115
116	116	(24) CROTONYL FENTANYL ((E)–N–(1–PHENETHYLPIPERIDIN –4–YL) 11
117	117	–N–PHENYLBUT –2–ENAMIDE); 12
118	118
119	119	(25) CYCLOPENTYL FENTANYL (N–(1–PHENETHYLPIPERIDIN –4–YL) 13
120	120	–N–PHENYLCYCLOPENTANECA RBOXAMIDE); 14
121	121
122	122	(26) CYCLOPROPYL FENTANYL (N–(1–PHENETHYLPIPERIDIN –4–YL) 15
123	123	–N–PHENYLCYCLOPROPANECA RBOXAMIDE); 16
124	124
125	125	[(22)] (27) dextromoramide; 17
126	126
127	127	[(23)] (28) diampromide; 18
128	128
129	129	[(24)] (29) diethylthiambutene; 19
130	130
131	131	[(25)] (30) difenoxin; 20
132	132
133	133	[(26)] (31) dimenoxadol; 21
134	134
135	135	[(27)] (32) dimepheptanol; 22
136	136
137	137	[(28)] (33) dimethylthiambutene; 23
138	138
139	139	[(29)] (34) dioxaphetyl butyrate; 24
140	140
141	141	[(30)] (35) dipipanone; 25
142	142
143	143	[(31)] (36) ethylmethylthiambutene; 26
144	144	4 SENATE BILL 189
145	145
146	146
147	147	[(32)] (37) etonitazene; 1
148	148
149	149	[(33)] (38) etoxeridine; 2
150	150
151	151	(39) FENTANYL CARBAMATE (ETHYL (1–PHENETHYLPIPERIDIN 3
152	152	–4–YL)(PHENYL)CARBAMATE ); 4
153	153
154	154	[(34)] (40) 4–Fluoroisobutyryl fentanyl (N –(4–fluorophenyl)–N–(1 5
155	155	– phenethylpiperidin–4–yl)isobutyramide; 6
156	156
157	157	(41) 2′–FLUORO ORTHO –FLUOROFENTANYL (N–(1–(2 7
158	158	–FLUOROPHENETHYL )PIPERIDIN–4–YL)–N–(2–FLUOROPHENYL )PROPIONAMIDE ; 8
159	159	ALSO KNOWN AS 2′–FLUORO 2–FLUOROFENTANYL ); 9
160	160
161	161	[(35)] (42) furanyl fentanyl (N –(1–phenethylpiperidin–4–yl)–N 10
162	162	–phenylfuran–2–carboxamide); 11
163	163
164	164	[(36)] (43) furethidine; 12
165	165
166	166	[(37)] (44) hydroxypethidine; 13
167	167
168	168	(45) ISOBUTYRYL FENTANYL (N–(1–PHENETHYLPIPERIDIN –4–YL) 14
169	169	–N–PHENYLISOBUTYRAMIDE ); 15
170	170
171	171	[(38)] (46) ketobemidone; 16
172	172
173	173	[(39)] (47) levomoramide; 17
174	174
175	175	[(40)] (48) levophenacylmorphan; 18
176	176
177	177	(49) METHOXYACETYL FENTAN YL (2–METHOXY–N–(1 19
178	178	–PHENETHYLPIPERIDIN –4–YL)–N–PHENYLACETAMIDE ); 20
179	179
180	180	(50) 4′–METHYL ACETYL FENTAN YL (N–(1–(4 21
181	181	–METHYLPHENETHYL )PIPERIDIN–4–YL)–N–PHENYLACETAMIDE ); 22
182	182
183	183	[(41)] (51) 3–methylfentanyl (N –[3–methyl–1–(2–phenylethyl) 23
184	184	–4–piperidyl]–N–phenylpropanamide); 24
185	185
186	186	[(42)] (52) 3–methylthiofentanyl (N–[3 25
187	187	–METHYL–1–(2–THIENYLETHYL )–4–PIPERIDINYL]–N–PHENYLPROPANAMIDE ); 26
188	188
189	189	[(43)] (53) morpheridine; 27
190	190
191	191	[(44)] (54) MPPP (1–methyl–4–phenyl–4–propionoxypiperidine); 28 SENATE BILL 189 5
192	192
193	193
194	194
195	195	[(45)] (55) mt–45 (1–cyclohexyl–4–(1,2–diphenylethyl)piperazine); 1
196	196
197	197	[(46)] (56) noracymethadol; 2
198	198
199	199	[(47)] (57) norlevorphanol; 3
200	200
201	201	[(48)] (58) normethadone; 4
202	202
203	203	[(49)] (59) norpipanone; 5
204	204
205	205	[(50)] (60) ocfentanil (N –(2–fluorophenyl)–2–methoxy–N–(1 6
206	206	– phenethylpiperidin–4–yl)acetamide); 7
207	207
208	208	(61) ORTHO–FLUOROACRYL FENTANYL (N–(2–FLUOROPHENYL )–N 8
209	209	–(1–PHENETHYLPIPERIDIN –4–YL)ACRYLAMIDE ); 9
210	210
211	211	(62) ORTHO–FLUOROBUTYRYL FENTAN YL (N–(2–FLUOROPHENYL )–10
212	212	N–(1–PHENETHYLPIPERIDIN –4–YL)BUTYRAMIDE ; ALSO KNOWN AS 2 11
213	213	–FLUOROBUTYRYL FENTAN YL); 12
214	214
215	215	(63) ORTHO–FLUOROFENTANYL (N–(2–FLUOROPHENYL )–N 13
216	216	–(1–PHENETHYLPIPERIDIN –4–YL)PROPIONAMIDE ); ALSO KNOWN AS 2 14
217	217	–FLUOROFENTANYL); 15
218	218
219	219	(64) ORTHO–FLUOROISOBUTYRYL FEN TANYL (N–(2 16
220	220	–FLUOROPHENYL )–N–(1–PHENETHYLPIPERIDIN –4–YL)ISOBUTYRAMIDE ); 17
221	221
222	222	(65) ORTHO–METHYL ACETYLFENTANY L (N–(2–METHYLPHENYL )–N–18
223	223	(1–PHENETHYLPIPERIDIN –4–YL)ACETAMIDE; ALSO KNOWN AS 2–METHYL 19
224	224	ACETYLFENTANYL ); 20
225	225
226	226	(66) ORTHO–METHYL METHOXYACETYL FENTANYL (2–METHOXY–N 21
227	227	–(2–METHYLPHENYL )–N–(1–PHENETHYLPIPERIDIN –4–YL)ACETAMIDE; ALSO 22
228	228	KNOWN AS 2–METHYL METHOXYACETYL FENTANYL); 23
229	229
230	230	(67) PARA–CHLOROISOBUTYRYL FEN TANYL (N–(4–CHLOROPHENYL ) 24
231	231	–N–(1–PHENETHYLPIPERIDIN –4–YL)ISOBUTYRAMIDE); 25
232	232
233	233	(68) PARA–FLUOROBUTYRYL FENTAN YL (N–(4–FLUOROPHENYL )–N 26
234	234	–(1–PHENETHYLPIPERIDIN –4–YL)BUTYRAMIDE ); 27
235	235
236	236	[(51)] (69) para–fluorofentanyl (N–(4–fluorophenyl)–N–[1–(2–phenethyl) 28
237	237	–4– piperidinyl] propanamide; 29 6 SENATE BILL 189
238	238
239	239
240	240
241	241	(70) PARA–FLUORO FURANYL FENTA NYL (N–(4–FLUOROPHENYL )–N–1
242	242	(1–PHENETHYLPIPERIDIN –4–YL)FURAN–2–CARBOXAMIDE ); 2
243	243
244	244	(71) PARA–METHOXYBUTYRYL FENTA NYL (N–(4–METHOXYPHENYL ) 3
245	245	–N–(1–PHENETHYLPIPERIDIN –4–YL)BUTYRAMIDE ); 4
246	246
247	247	(72) PARA–METHYLFENTANYL (N–(4–METHYLPHENYL )–N 5
248	248	–(1–PHENETHYLPIPERIDIN –4–YL)PROPIONAMIDE; ALSO KNOWN AS 4– 6
249	249	METHYLFENTANYL ); 7
250	250
251	251	[(52)] (73) PEPAP (1–(–2–phenethyl)–4–phenyl–4–acetoxypiperidine); 8
252	252
253	253	[(53)] (74) phenadoxone; 9
254	254
255	255	[(54)] (75) phenampromide; 10
256	256
257	257	[(55)] (76) phenomorphan; 11
258	258
259	259	[(56)] (77) phenoperidine; 12
260	260
261	261	(78) PHENYL FENTANYL (N–(1–PHENETHYLPIPERIDIN –4–YL) 13
262	262	–N–PHENYLBENZAMIDE ; ALSO KNOWN AS BENZOY L FENTANYL); 14
263	263
264	264	[(57)] (79) piritramide; 15
265	265
266	266	[(58)] (80) proheptazine; 16
267	267
268	268	[(59)] (81) properidine; 17
269	269
270	270	[(60)] (82) propiram; 18
271	271
272	272	[(61)] (83) racemoramide; 19
273	273
274	274	[(62)] (84) tetrahydrofuranyl fentanyl (N–(1–phenethylpiperidin–4–yl)–N 20
275	275	– phenyltetrahydrofuran–2–carboxamide); 21
276	276
277	277	[(63)] (85) thiofentanyl (N–PHENYL–N–[1–(2 22
278	278	–THIENYL)ETHYL–4–PIPERIDINYL]PROPANAMIDE ); 23
279	279
280	280	(86) THIOFURANYL FENTANYL (N–(1–PHENETHYLPIPERIDIN –4–YL) 24
281	281	–N–PHENYLTHIOPHENE –2–CARBOXAMIDE ; ALSO KNOWN AS 2–THIOFURANYL 25
282	282	FENTANYL; THIOPHENE FENTANYL ); 26
283	283
284	284	[(64)] (87) tilidine; 27 SENATE BILL 189 7
285	285
286	286
287	287
288	288	[(65)] (88) trimeperidine; [and] 1
289	289
290	290	[(66)] (89) U–47700 (3,4–dichloro–N–[2–(dimethylamino)cyclohexyl]–N 2
291	291	– methylbenzamide); AND 3
292	292
293	293	(90) VALERYL FENTANYL (N–(1–PHENETHYLPIPERIDIN –4–YL) 4
294	294	–N–PHENYLPENTANAMIDE ). 5
295	295
296	296	(c) Unless specifically excepted under this subtitle or listed in another schedule, 6
297	297	any of the following opium derivatives, including their salts, isomers, and salts of isomers, 7
298	298	whenever the existence of such salts, isomers, or salts of isomers is possible within the 8
299	299	specific chemical designation, are substances listed in Schedule I: 9
300	300
301	301	(1) acetorphine; 10
302	302
303	303	(2) acetyldihydrocodeine; 11
304	304
305	305	(3) benzylmorphine; 12
306	306
307	307	(4) codeine methylbromide; 13
308	308
309	309	(5) codeine–N–oxide; 14
310	310
311	311	(6) cyprenorphine; 15
312	312
313	313	(7) desomorphine; 16
314	314
315	315	(8) dihydromorphine; 17
316	316
317	317	(9) drotebanol; 18
318	318
319	319	(10) etorphine (except hydrochloride salt); 19
320	320
321	321	(11) heroin; 20
322	322
323	323	(12) hydromorphinol; 21
324	324
325	325	(13) methyldesorphine; 22
326	326
327	327	(14) methyldihydromorphine; 23
328	328
329	329	(15) morphine methylbromide; 24
330	330
331	331	(16) morphine methylsulfonate; 25
332	332
333	333	(17) morphine–N–oxide; 26 8 SENATE BILL 189
334	334
335	335
336	336
337	337	(18) myrophine; 1
338	338
339	339	(19) nicocodeine; 2
340	340
341	341	(20) nicomorphine; 3
342	342
343	343	(21) normorphine; 4
344	344
345	345	(22) pholcodine; and 5
346	346
347	347	(23) thebacon. 6
348	348
349	349	(d) Unless specifically excepted under this subtitle or listed in another schedule, 7
350	350	any material, compound, mixture, or preparation that contains any quantity of the 8
351	351	following hallucinogenic substances, or that contains any of its salts, isomers, including 9
352	352	optical, position, and geometric isomers, or salts of isomers, whenever the existence of such 10
353	353	salts, isomers, or salts of isomers is possible within the specific chemical designation, is a 11
354	354	substance listed in Schedule I: 12
355	355
356	356	(1) alpha–ethyltryptamine; 13
357	357
358	358	(2) 4–bromo–2,5–dimethoxy–amphetamine; 14
359	359
360	360	(3) 4–bromo–2,5–dimethoxyphenethylamine; 15
361	361
362	362	(4) 2,5–dimethoxyamphetamine; 16
363	363
364	364	(5) 2,5–dimethoxy–4–ethylamphetamine (DOET); 17
365	365
366	366	(6) 2,5–dimethoxy–4–(n)–propylthiophenethylamine (2C–T–7); 18
367	367
368	368	(7) 4–methoxyamphetamine (PMA); 19
369	369
370	370	(8) 5–methoxy–3,4–methylenedioxy–amphetamine; 20
371	371
372	372	(9) 4–methyl–2,5–dimethoxy–amphetamine; 21
373	373
374	374	(10) 3,4–methylenedioxy amphetamine; 22
375	375
376	376	(11) 3,4–methylenedioxymethamphetamine (MDMA); 23
377	377
378	378	(12) 3,4–methylenedioxy–N–ethylamphetamine (MDA); 24
379	379
380	380	(13) N–hydroxy–3,4–methylenedioxyamphetamine; 25
381	381
382	382	(14) 3,4,5–trimethoxyamphetamine; 26 SENATE BILL 189 9
383	383
384	384
385	385
386	386	(15) 5–methoxy–N, N–dimethyltryptamine; 1
387	387
388	388	(16) alpha–methyltryptamine (AMT); 2
389	389
390	390	(17) bufotenine; 3
391	391
392	392	(18) diethyltryptamine (DET); 4
393	393
394	394	(19) dimethyltryptamine (DMT); 5
395	395
396	396	(20) 5–methoxy–N, N–diisopropyltryptamine (5–MeO–DIPT); 6
397	397
398	398	(21) ibogaine; 7
399	399
400	400	(22) lysergic acid diethylamide; 8
401	401
402	402	(23) marijuana; 9
403	403
404	404	(24) mescaline; 10
405	405
406	406	(25) parahexyl–7374; 11
407	407
408	408	(26) peyote (meaning all parts of the plant presently classified botanically 12
409	409	as Lophophora williamsii lemaire, whether growing or not, the seeds thereof, any extract 13
410	410	from any part of such plant, and every compound, manufacture, salt, derivative, mixture, 14
411	411	or preparation of such plant, its seeds, or extracts); 15
412	412
413	413	(27) N–ethyl–3–piperidyl benzilate; 16
414	414
415	415	(28) N–methyl–3–piperidyl benzilate; 17
416	416
417	417	(29) psilocybin; 18
418	418
419	419	(30) psilocyn; 19
420	420
421	421	(31) tetrahydrocannabinols; 20
422	422
423	423	(32) ethylamine analog of phencyclidine (N –ethyl–1 21
424	424	–phenylcyclohexylamine); 22
425	425
426	426	(33) pyrrolidine analog of phencyclidine (1 –(1–phenylcyclohexyl) 23
427	427	– pyrrolidine); 24
428	428
429	429	(34) thiophene analog of phencyclidine (1 –[1–(2–thienyl)–cyclohexyl] 25
430	430	– piperidine); 26
431	431	10 SENATE BILL 189
432	432
433	433
434	434	(35) 1–[1–(2–thienyl)cyclohexyl]pyrrolidine; 1
435	435
436	436	(36) 4–methylmethcathinone (mephedrone); 2
437	437
438	438	(37) 3, 4–methylenedioxypyrovalerone (MDPV); 3
439	439
440	440	(38) 2–(2,5–dimethoxy–4–ethylphenyl) ethanamine (2C–E); 4
441	441
442	442	(39) 2–(2,5–dimethoxy–4–methylphenyl) ethanamine (2C–D); 5
443	443
444	444	(40) 2–(4–chloro–2,5–dimethoxyphenyl) ethanamine (2C–C); 6
445	445
446	446	(41) 2–(4–iodo–2,5–dimethoxyphenyl) ethanamine (2C–I); 7
447	447
448	448	(42) 2–[4–(ethylthio)–2,5–dimethoxyphenyl] ethanamine (2C–T–2); 8
449	449
450	450	(43) 2–[4–(isopropylthio)–2,5–dimethoxyphenyl] ethanamine (2C–T–4); 9
451	451
452	452	(44) 2–(2,5–dimethoxyphenyl) ethanamine (2C–H); 10
453	453
454	454	(45) 2–(2,5–dimethoxy–4–nitro–phenyl) ethanamine (2C–N); 11
455	455
456	456	(46) 2–(2,5–dimethoxy–4–(n)–propylphenyl) ethanamine (2C–P); 12
457	457
458	458	(47) 3,4–methylenedioxy–N–methylcathinone (methylone); 13
459	459
460	460	(48) (1–pentyl–1H–indol–3–yl) (2,2,3,3–tetramethylcyclopropyl) methanone 14
461	461	(UR–144); 15
462	462
463	463	(49) [1–(5–fluoro–pentyl)–1H–indol–3–yl](2,2,3,3–tetramethylcyclopropyl) 16
464	464	methanone (5–fluoro–UR–144, XLR11); 17
465	465
466	466	(50) N–(1–adamantyl)–1–pentyl–1H–indazole–3–carboxamide (APINACA, 18
467	467	AKB48); 19
468	468
469	469	(51) quinolin–8–yl 1–pentyl–1H–indole–3–carboxylate (PB–22); 20
470	470
471	471	(52) quinolin–8–yl 1–(5–fluoropentyl)–1H–indole–3–carboxylate (5–fluoro 21
472	472	– PB–22); 22
473	473
474	474	(53) N–(1–amino–3–methyl–1–oxobutan–2–yl)–1–(4–fluorobenzyl)–1H– 23
475	475	indazole–3–carboxamide (AB–FUBINACA); 24
476	476
477	477	(54) N–(1–amino–3, 3 –dimethyl–1–oxobutan–2–yl)–1–pentyl–1H 25
478	478	–indazole–3–carboxamide (ADB–PINACA); 26
479	479
480	480	(55) 2–(4–iodo–2,5–dimethoxyphenyl)–N–(2–methoxybenzyl) ethanamine 27 SENATE BILL 189 11
481	481
482	482
483	483	(25I–NBOMe); 1
484	484
485	485	(56) 2–(4–chloro–2,5–dimethoxyphenyl)–N–(2–methoxybenzyl) ethanamine 2
486	486	(25C–NBOMe); 3
487	487
488	488	(57) 2–(4–bromo–2,5–dimethoxyphenyl)–N–(2–methoxybenzyl) ethanamine 4
489	489	(25B–NBOMe); 5
490	490
491	491	(58) marijuana extract (meaning an extract containing one or more 6
492	492	cannabinoids that has been derived from any plant of the genus cannabis, other than the 7
493	493	separated resin, whether crude or purified, obtained from the plant); 8
494	494
495	495	(59) 4–methyl–N–ethylcathinone (4–MEC); 9
496	496
497	497	(60) 4–methyl–alpha–pyrrolidinopropiophenone (4–MePPP); 10
498	498
499	499	(61) alpha–pyrrolidinopentiophenone (alpha–PVP); 11
500	500
501	501	(62) 1–(1,3–benzodioxol–5–yl)–2–(methylamino) butan–1–one (butylone); 12
502	502
503	503	(63) 2–(methylamino)–1–phenylpentan–1–one (pentedrone); 13
504	504
505	505	(64) 1–(1,3–benzodioxol–5–yl)–2–(methylamino) pentan–1–one (pentylone); 14
506	506
507	507	(65) 4–fluoro–N–methylcathinone (flephedrone); 15
508	508
509	509	(66) 3–fluoro–N–methylcathinone (3–FMC); 16
510	510
511	511	(67) 1–(naphthalen–2–yl)–2–(pyrrolidin–1–yl)pentan–1–one (naphyrone); 17
512	512
513	513	(68) alpha–pyrrolidinobutiophenone (alpha–PBP); 18
514	514
515	515	(69) N–(1–amino–3–methyl–1–oxobutan–2–yl)–1–(cyclohexylmethyl)–1H– 19
516	516	indazole–3–carboxamide (AB–CHMINACA); 20
517	517
518	518	(70) N–(1–amino–3–methyl–1–oxobutan–2–yl)–1–pentyl–1H–indazole–3– 21
519	519	carboxamide (AB–PINACA); 22
520	520
521	521	(71) [1–(5–fluoropentyl)–1H–indazol–3–yl](naphthalen–1–yl)methanone 23
522	522	(THJ–2201); [and] 24
523	523
524	524	(72) N–(1–amino–3,3–dimethyl–1–oxobutan–2–yl)–1–(cyclohexylmethyl)–25
525	525	1H–indazole–3–carboxamide (MAB–CHMINACA); 26
526	526
527	527	(73) METHYL 2–(1–(5–FLUOROPENTYL )–1H–NDAZOLE–3 27
528	528	–CARBOXAMID O)–3,3–DIMETHYLBUTANOATE (OTHER NAMES : 5F–ADB; 5F–28
529	529	MDMB–PINACA); 29 12 SENATE BILL 189
530	530
531	531
532	532
533	533	(74) METHYL 2–(1–(5–FLUOROPENTYL )–1H–INDAZOLE–3 1
534	534	–CARBOXAMIDO )–3–METHYLBUTANOATE (OTHER NAMES : 5F–AMB); 2
535	535
536	536	(75) N–(ADAMANTAN –1–YL)–1–(5–FLUOROPENTYL )–1H–INDAZOLE– 3
537	537	3–CARBOXAMIDE (OTHER NAMES: 5F–APINACA, 5F–AKB48); 4
538	538
539	539	(76) N–(1–AMINO–3,3–DIMETHYL–1–OXOBUTAN–2–YL)–1–(4–5
540	540	FLUOROBENZYL )–1H–INDAZOLE–3–CARBOXAMIDE (OTHER NAMES : ADB–6
541	541	FUBINACA); 7
542	542
543	543	(77) METHYL 2–(1–(CYCLOHEXYLMETHYL )–1H–INDOLE–3 8
544	544	–CARBOXAMIDO )–3,3–DIMETHYLBUTANOATE (OTHER NAMES : MDMBA–CHMICA, 9
545	545	MMB–CHMINACA); 10
546	546
547	547	(78) METHYL 2–(1–(4–FLUOROBENZYL )–1H–INDAZOLE–3 11
548	548	–CARBOXAMIDO )–3,3–DIMETHYLBUTANOATE (OTHER NAMES : MDMB–12
549	549	FUBINACA); 13
550	550
551	551	(79) METHYL 2–(1–(4–FLUOROBENZYL )–1H–INDAZOLE–3 14
552	552	–CARBOXAMIDO )–3–METHYLBUTANOATE , (FUB–AMB, MMB–FUBINACA, AMB–15
553	553	FUBINACA); 16
554	554
555	555	(80) 1–(1,3–BENZODIOXOL –5–YL)–2–(ETHYLAMINO )PROPAN–1–ONE 17
556	556	(ETHYLONE); 18
557	557
558	558	(81) NAPHTHALEN –1–YL 1–(5–FLUOROPENTYL )–1H–INDOLE–3–19
559	559	CARBOXYLATE (OTHER NAMES : NM2201; CBL2201); 20
560	560
561	561	(82) N–(1–AMINO–3–METHYL–1–OXOBUTAN–2–YL)–1–(5–21
562	562	FLUOROPENTYL )–1H–INDAZOLE–3–CARBOXAMIDE (OTHER NAME : 5F–AB–22
563	563	PINACA); 23
564	564
565	565	(83) 1–(4–CYANOBUTYL )–N–(2–PHENYLPROPAN –2–YL)–1H–24
566	566	INDAZOLE–3–CARBOXAMIDE (OTHER NAMES : 4–CN–CUMYL–BUTINACA; 4 25
567	567	–CYANO–CUMYL–BUTINACA; 4–CN–CUMYL BINACA; CUMYL–4–CN–26
568	568	BINACA; SGT–78); 27
569	569
570	570	(84) METHYL 2–(1–(CYCLOHEXYLMETHYL )–1H–INDOLE–3 28
571	571	–CARBOXAMIDO )–3–METHYLBUTANOATE (OTHER NAMES : MMB–CHMICA; AMB–29
572	572	CHMICA); 30
573	573
574	574	(85) 1–(5–FLUOROPENTYL )–N–(2–PHENYLPROPAN –2–YL)–1H–31
575	575	PYRROLO[2,3B]PYRIDINE–3–CARBOXAMIDE (OTHER NAME : 5F–CUMYL–32 SENATE BILL 189 13
576	576
577	577
578	578	P7AICA); 1
579	579
580	580	(86) N–ETHYLPENTYLONE (OTHER NAMES: EPHYLONE, 1–(1,3–2
581	581	BENZODIOXOL –5–YL)–2–(ETHYLAMINO )PENTAN–1–ONE); 3
582	582
583	583	(87) METHYL 2–(1–(4–FLUOROBUTYL )–1H–INDAZOLE–3 4
584	584	–CARBOXAMIDO )–3,3–DIMETHYLBUTANOATE (4F–MDMB–BINACA, 4F–MDMB–5
585	585	BUTINACA); AND 6
586	586
587	587	(88) 1–(4–METHOXYPHENYL )–N–METHYLPROPAN –2–AMINE (OTHER 7
588	588	NAMES: PARA–METHOXYMETHAMPHETAMI NE, PMMA). 8
589	589
590	590	(e) Unless specifically excepted under this subtitle or listed in another schedule, 9
591	591	a material, compound, mixture, or preparation that contains any quantity of the following 10
592	592	substances having depressant effects on the central nervous system, or that contains its 11
593	593	salts, isomers, or salts of isomers, whenever the existence of such salts, isomers, or salts of 12
594	594	isomers is possible within the specific chemical designation, is a substance listed in 13
595	595	Schedule I: 14
596	596
597	597	(1) gamma–hydroxybutyric acid (GHB); 15
598	598
599	599	(2) mecloqualone; and 16
600	600
601	601	(3) methaqualone. 17
602	602
603	603	(f) Unless specifically excepted or listed in another schedule, any material, 18
604	604	compound, mixture, or preparation that contains any quantity of the following substances 19
605	605	having a stimulant effect on the central nervous system, or that contains its salts, isomers, 20
606	606	or salts of isomers, is a substance listed in Schedule I: 21
607	607
608	608	(1) aminorex; 22
609	609
610	610	(2) N–benzylpiperazine (BZP); 23
611	611
612	612	(3) cathinone; 24
613	613
614	614	(4) fenethylline; 25
615	615
616	616	(5) methcathinone; 26
617	617
618	618	(6) [(+)cis–4–methylaminorex ((+)cis–4,5–dihydro–4–methyl–5–phenyl–2 27
619	619	– oxazolamine)] (±)CIS–4–METHYLAMINOREX ((±)CIS–4,5–DIHYDRO–4–METHYL–5– 28
620	620	PHENYL–2–OXAZOLAMINE ); 29
621	621
622	622	(7) N–ethylamphetamine; and 30
623	623	14 SENATE BILL 189
624	624
625	625
626	626	(8) N, N–dimethylamphetamine. 1
627	627
628	628	(g) Unless specifically excepted under this subtitle or listed in another schedule, 2
629	629	any material, compound, mixture, or preparation that contains any quantity of the 3
630	630	following substances, or that contains their salts, isomers, or salts of isomers, whenever the 4
631	631	existence of such salts, isomers, or salts of isomers is possible within the specific chemical 5
632	632	designation, is a substance listed in Schedule I: 6
633	633
634	634	(1) 5–(1, 1–dimethylheptyl)–2–[(1R,3S)–3–hydroxycyclohexyl]–phenol 7
635	635	(CP– 47,497); 8
636	636
637	637	(2) 5–(1,1–dimethyloctyl)–2–[(1R,3S)–3–hydroxycyclohexyl]–phenol (CP 9
638	638	– 47,497 C8 homolog); 10
639	639
640	640	(3) 1–pentyl–3–(1–naphthoyl) indole (JWH–018 and AM678); 11
641	641
642	642	(4) 1–butyl–3–(1–naphthoyl) indole (JWH–073); 12
643	643
644	644	(5) 1–hexyl–3–(1–naphthoyl) indole (JWH–019); 13
645	645
646	646	(6) 1–[2–(4–morpholinyl)ethyl]–3–(1–naphthoyl) indole (JWH–200); 14
647	647
648	648	(7) 1–pentyl–3–(2–methoxyphenylacetyl) indole (JWH–250); 15
649	649
650	650	(8) 1–pentyl–3–[1–(4–methoxynaphthoyl)] indole (JWH–081); 16
651	651
652	652	(9) 1–pentyl–3–(4–methyl–1–naphthoyl) indole (JWH–122); 17
653	653
654	654	(10) 1–pentyl–3–(4–chloro–1–naphthoyl) indole (JWH–398); 18
655	655
656	656	(11) 1–(5–fluoropentyl)–3–(1–naphthoyl) indole (AM2201); 19
657	657
658	658	(12) 1–(5–fluoropentyl)–3–(2–iodobenzoyl) indole (AM694); 20
659	659
660	660	(13) 1–pentyl–3–[(4–methoxy)–benzoyl] indole (SR–19 and RCS–4); 21
661	661
662	662	(14) 1–cyclohexylethyl–3–(2–methoxyphenylacetyl) indole 7008 (SR–18 and 22
663	663	RCS–8); and 23
664	664
665	665	(15) 1–pentyl–3–(2–chlorophenylacetyl) indole (JWH–203). 24
666	666
667	667	(h) (1) In this subsection: 25
668	668
669	669	(i) “controlled dangerous substance analogue” means a substance: 26
670	670
671	671	1. that has a chemical structure substantially similar to the 27
672	672	chemical structure of a controlled dangerous substance listed in Schedule I or Schedule II; 28 SENATE BILL 189 15
673	673
674	674
675	675	and 1
676	676
677	677	2. that has a stimulant, depressant, or hallucinogenic effect 2
678	678	on the central nervous system that is substantially similar to or greater than the stimulant, 3
679	679	depressant, or hallucinogenic effect on the central nervous system of a controlled dangerous 4
680	680	substance listed in Schedule I or Schedule II; but 5
681	681
682	682	(ii) “controlled dangerous substance analogue” does not include: 6
683	683
684	684	1. a controlled dangerous substance; 7
685	685
686	686	2. a substance for which there is an approved new drug 8
687	687	application; or 9
688	688
689	689	3. a substance exempted for investigational use under § 506 10
690	690	of the Federal Food, Drug, and Cosmetic Act. 11
691	691
692	692	(2) To the extent intended for human consumption, each controlled 12
693	693	dangerous substance analogue is a substance listed in Schedule I. 13
694	694
695	695	(i) The Department may not add a substance to Schedule I under § 5–202 of this 14
696	696	title unless the Department finds: 15
697	697
698	698	(1) a high potential for abuse of the substance; 16
699	699
700	700	(2) no accepted medical use in the United States for the substance; and 17
701	701
702	702	(3) a lack of accepted safety for use of the substance under medical 18
703	703	supervision. 19
704	704
705	705	5–403. 20
706	706
707	707	(a) Schedule II consists of each controlled dangerous substance: 21
708	708
709	709	(1) listed in this section; 22
710	710
711	711	(2) added to Schedule II by the Department under § 5–202(b) of this title; 23
712	712	or 24
713	713
714	714	(3) designated as a Schedule II controlled dangerous substance by the 25
715	715	federal government unless the Department objects under § 5–202(f) of this title. 26
716	716
717	717	(b) Unless specifically excepted or unless listed in another schedule, any of the 27
718	718	following substances whether produced directly or indirectly by extraction from substances 28
719	719	of vegetable origin, or independently by means of chemical synthesis, or by a combination 29
720	720	of extraction and chemical synthesis: 30
721	721	16 SENATE BILL 189
722	722
723	723
724	724	(1) opium and opiate, and any salt, compound, derivative, or preparation 1
725	725	of opium or opiate excluding apomorphine, thebaine–derived butorphanol, dextrorphan, 2
726	726	nalbuphine, naldemedine, nalmefene, naloxegol, naloxone, and naltrexone, and their 3
727	727	respective salts, but including the following: 4
728	728
729	729	(i) codeine; 5
730	730
731	731	(ii) dihydroetorphine; 6
732	732
733	733	(iii) ethylmorphine; 7
734	734
735	735	(iv) etorphine hydrochloride; 8
736	736
737	737	(v) granulated opium; 9
738	738
739	739	(vi) hydrocodone; 10
740	740
741	741	(vii) hydromorphone; 11
742	742
743	743	(viii) metopon; 12
744	744
745	745	(ix) morphine; 13
746	746
747	747	(x) NOROXYMORPHONE ; 14
748	748
749	749	(XI) opium extracts; 15
750	750
751	751	[(xi)] (XII) opium fluid; 16
752	752
753	753	[(xii)] (XIII) oripavine; 17
754	754
755	755	[(xiii)] (XIV) oxycodone; 18
756	756
757	757	[(xiv)] (XV) oxymorphone; 19
758	758
759	759	[(xv)] (XVI) powdered opium; 20
760	760
761	761	[(xvi)] (XVII) raw opium; 21
762	762
763	763	[(xvii)] (XVIII) thebaine; and 22
764	764
765	765	[(xviii)] (XIX) tincture of opium; 23
766	766
767	767	(2) any salt, compound, derivative, or preparation thereof which is 24
768	768	chemically equivalent or identical with any of the substances referred to in item (1) of this 25 SENATE BILL 189 17
769	769
770	770
771	771	subsection, except that these substances may not include the isoquinoline alkaloids of 1
772	772	opium; 2
773	773
774	774	(3) opium poppy and poppy straw; 3
775	775
776	776	(4) coca leaves and any salt, compound, derivative, or preparation of coca 4
777	777	leaves, including cocaine and ecgonine and their salts, isomers, derivatives and salts of 5
778	778	isomers and derivatives, and any salt, compound, derivative, or preparation thereof which 6
779	779	is chemically equivalent or identical with any of these substances, except that the 7
780	780	substances may not include: 8
781	781
782	782	(i) decocainized coca leaves or extraction of coca leaves, which 9
783	783	extractions do not contain cocaine or ecgonine; or 10
784	784
785	785	(ii) ioflupane; and 11
786	786
787	787	(5) concentrate of poppy straw (the crude extract of poppy straw in either 12
788	788	liquid, solid, or powder form which contains the phenanthrene alkaloids of the opium 13
789	789	poppy). 14
790	790
791	791	(c) Unless specifically excepted or unless in another schedule any of the following 15
792	792	opiates, including its isomers, esters, ethers, salts, and salts of isomers, esters, and ethers 16
793	793	whenever the existence of such isomers, esters, ethers, and salts is possible within the 17
794	794	specific chemical designation, dextrorphan and levopropoxyphene excepted: 18
795	795
796	796	(1) alfentanil; 19
797	797
798	798	(2) alphaprodine; 20
799	799
800	800	(3) anileridine; 21
801	801
802	802	(4) bezitramide; 22
803	803
804	804	(5) bulk dextropropoxyphene (non–dosage forms); 23
805	805
806	806	(6) carfentanil; 24
807	807
808	808	(7) dihydrocodeine; 25
809	809
810	810	(8) diphenoxylate; 26
811	811
812	812	(9) fentanyl; 27
813	813
814	814	(10) isomethadone; 28
815	815
816	816	(11) levo–alphacetylmethadol; 29
817	817	18 SENATE BILL 189
818	818
819	819
820	820	(12) levomethorphan; 1
821	821
822	822	(13) levorphanol; 2
823	823
824	824	(14) metazocine; 3
825	825
826	826	(15) methadone; 4
827	827
828	828	(16) methadone – intermediate, 4–cyano–2–dimethylamino–4, 4–diphenyl 5
829	829	butane; 6
830	830
831	831	(17) moramide – intermediate, 2–methyl–3– morpholino–1, 1 7
832	832	– diphenylpropane–carboxylic acid; 8
833	833
834	834	(18) OLICERIDINE (N–[(3–METHOXYTHIOPHEN –2–YL)METHYL] 9
835	835	({2–[(9R)–9–(PYRIDIN–2–YL)–6–OXASPIRO [4.5]DECAN–9–YL]ETHYL})AMINE 10
836	836	FUMARATE); 11
837	837
838	838	(19) pethidine (meperidine); 12
839	839
840	840	[(19)] (20) pethidine – intermediate – A, 4–cyano–1–methyl–4 13
841	841	– phenylpiperidine; 14
842	842
843	843	[(20)] (21) pethidine – intermediate – B, ethyl–4–phenylpiperidine–4 15
844	844	– carboxylate; 16
845	845
846	846	[(21)] (22) pethidine – intermediate – C, 1–methyl–4–phenylpiperidine–4 17
847	847	– carboxylic acid; 18
848	848
849	849	[(22)] (23) phenazocine; 19
850	850
851	851	[(23)] (24) piminodine; 20
852	852
853	853	[(24)] (25) racemethorphan; 21
854	854
855	855	[(25)] (26) racemorphan; 22
856	856
857	857	[(26)] (27) remifentanil; 23
858	858
859	859	[(27)] (28) sulfentanil; 24
860	860
861	861	[(28)] (29) tapentadol; and 25
862	862
863	863	[(29)] (30) thiafentanil. 26
864	864	SENATE BILL 189 19
865	865
866	866
867	867	(d) Unless specifically excepted under this subtitle or listed in another schedule, 1
868	868	a substance is listed in Schedule II if the substance includes a material, compound, mixture, 2
869	869	or preparation that contains any quantity of the following substances having a potential 3
870	870	for abuse associated with a stimulant effect on the central nervous system: 4
871	871
872	872	(1) amphetamine, its salts, optical isomers, and salts of its optical isomers; 5
873	873
874	874	(2) methamphetamine, its salts, isomer, and salts of isomers; 6
875	875
876	876	(3) phenmetrazine and its salts; 7
877	877
878	878	(4) methylphenidate; and 8
879	879
880	880	(5) lisdexamfetamine, its salts, isomers, and salts of isomers. 9
881	881
882	882	(e) Unless specifically excepted under this subtitle or listed in another schedule, 10
883	883	a substance is listed in Schedule II if the substance includes a material, compound, mixture, 11
884	884	or preparation that contains any quantity of the following substances having a depressant 12
885	885	effect on the central nervous system, including its salts, isomers, and salts of isomers 13
886	886	whenever the existence of such salts, isomers, and salts of isomers is possible within the 14
887	887	specific chemical designation: 15
888	888
889	889	(1) amobarbital; 16
890	890
891	891	(2) glutethimide; 17
892	892
893	893	(3) pentobarbital; 18
894	894
895	895	(4) phencyclidine; and 19
896	896
897	897	(5) secobarbital. 20
898	898
899	899	(f) [As] HALLUCINOGENIC SUBSTA NCES, AS listed in Schedule II under Title 21
900	900	21 of the Code of Federal Regulations. 22
901	901
902	902	(1) nabilone; and 23
903	903
904	904	(2) dronabinol [(–)–delta–9–trans tetrahydrocannabinol] in an oral 24
905	905	solution in a drug product approved for marketing by the United States Food and Drug 25
906	906	Administration. 26
907	907
908	908	(g) Unless specifically excepted or unless listed in another schedule, any material, 27
909	909	compound, mixture, or preparation which contains any quantity of the following 28
910	910	substances: 29
911	911
912	912	(1) immediate precursor to amphetamine and methamphetamine: 30
913	913	20 SENATE BILL 189
914	914
915	915
916	916	(i) phenylacetone; and 1
917	917
918	918	(ii) reserved; 2
919	919
920	920	(2) immediate precursors to phencyclidine (PCP): 3
921	921
922	922	(i) 1–phenylcyclohexylamine; and 4
923	923
924	924	(ii) 1–piperidinocyclohexanecarbonitrile (PCC); and 5
925	925
926	926	(3) immediate precursor to fentanyl: 6
927	927
928	928	(i) 4–anilino–N–phenethylpiperidine (ANPP); and 7
929	929
930	930	(ii) [reserved] N–PHENYL–N–(PIPERIDIN–4–YL)PROPIONAMIDE 8
931	931	(NORFENTANYL ). 9
932	932
933	933	(h) The Department may not add a substance to Schedule II under § 5–202 of this 10
934	934	title unless the Department finds: 11
935	935
936	936	(1) a high potential for abuse of the substance; 12
937	937
938	938	(2) currently accepted medical use of the substance in the United States, 13
939	939	or currently accepted medical use with severe restrictions; and 14
940	940
941	941	(3) evidence that abuse of the substance may lead to severe psychological 15
942	942	or physical dependence. 16
943	943
944	944	5–404. 17
945	945
946	946	(a) Schedule III consists of each controlled dangerous substance by whatever 18
947	947	official name, common or usual name, chemical name, or brand name designated: 19
948	948
949	949	(1) listed in this section; 20
950	950
951	951	(2) added to Schedule III by the Department under § 5–202(b) of this title; 21
952	952	or 22
953	953
954	954	(3) designated as a Schedule III controlled dangerous substance by the 23
955	955	federal government unless the Department objects under § 5–202(f) of this title. 24
956	956
957	957	(b) (1) Unless specifically excepted or listed in another schedule, a substance 25
958	958	is listed in Schedule III if the substance includes a material, compound, mixture, or 26
959	959	preparation that contains any quantity of the following substances having a stimulant 27
960	960	effect on the central nervous system: 28
961	961
962	962	(i) those compounds, mixtures, or preparations in dosage unit form 29 SENATE BILL 189 21
963	963
964	964
965	965	containing any stimulant substances listed in Schedule II, which compounds, mixtures, or 1
966	966	preparations were listed on August 25, 1971, as excepted compounds under § 1308.32 of the 2
967	967	Code of Federal Regulations, and any other drug of the quantitative composition shown in 3
968	968	that list for those drugs or that is the same except that it contains a lesser quantity of 4
969	969	controlled substances; 5
970	970
971	971	(ii) benzphetamine; 6
972	972
973	973	(iii) chlorphentermine; 7
974	974
975	975	(iv) clortermine; and 8
976	976
977	977	(v) phendimetrazine. 9
978	978
979	979	(2) Subject to paragraph (3) of this subsection, substances in Schedule III 10
980	980	include: 11
981	981
982	982	(i) a salt of a substance listed in this subsection; 12
983	983
984	984	(ii) an optical, position, or geometric isomer of a substance listed in 13
985	985	this subsection; or 14
986	986
987	987	(iii) a salt of an isomer of a substance listed in this subsection. 15
988	988
989	989	(3) Unless listed in another schedule, a salt, isomer, or salt of an isomer 16
990	990	described in paragraph (2) of this subsection may be included in Schedule III only if the 17
991	991	existence of the salts, isomers, and salts of isomers is possible within the specific chemical 18
992	992	designation. 19
993	993
994	994	(c) Unless listed in another schedule, a substance is listed in Schedule III if the 20
995	995	substance includes a material, compound, mixture, or preparation that contains any 21
996	996	quantity of the following substances having a potential for abuse associated with a 22
997	997	depressant effect on the central nervous system: 23
998	998
999	999	(1) any compound, mixture, or preparation containing: 24
1000	1000
1001	1001	(i) amobarbital; 25
1002	1002
1003	1003	(ii) secobarbital; 26
1004	1004
1005	1005	(iii) pentobarbital; or 27
1006	1006
1007	1007	(iv) any salt thereof and one or more other active medicinal 28
1008	1008	ingredients that are not listed in any schedule; 29
1009	1009
1010	1010	(2) any suppository dosage form containing: 30
1011	1011	22 SENATE BILL 189
1012	1012
1013	1013
1014	1014	(i) amobarbital; 1
1015	1015
1016	1016	(ii) secobarbital; 2
1017	1017
1018	1018	(iii) pentobarbital; or 3
1019	1019
1020	1020	(iv) any salt of any of these drugs and approved by the U.S. Food and 4
1021	1021	Drug Administration for marketing only as a suppository; 5
1022	1022
1023	1023	(3) except those substances that are specifically listed in other schedules, 6
1024	1024	a substance that contains any quantity of a derivative of barbituric acid, a salt of a 7
1025	1025	derivative of a barbituric acid, or butalbital, including, with one or more active, nonnarcotic 8
1026	1026	ingredients in recognized therapeutic amounts, (Fioricet) and (Fiorinal); 9
1027	1027
1028	1028	(4) chlorhexadol; 10
1029	1029
1030	1030	(5) embutramide; 11
1031	1031
1032	1032	(6) any drug product containing gamma hydroxybutyric acid, including its 12
1033	1033	salts, isomers, and salts of isomers, for which an application is approved under Section 505 13
1034	1034	of the Federal Food, Drug, and Cosmetic Act; 14
1035	1035
1036	1036	(7) ketamine, its salts, isomers, and salts of isomers; 15
1037	1037
1038	1038	(8) lysergic acid; 16
1039	1039
1040	1040	(9) lysergic acid amide; 17
1041	1041
1042	1042	(10) methyprylon; 18
1043	1043
1044	1044	(11) perampanel, and its salts, isomers, and salts of isomers (FYCOMPA); 19
1045	1045
1046	1046	(12) sulfondiethylmethane; 20
1047	1047
1048	1048	(13) sulfonethylmethane; 21
1049	1049
1050	1050	(14) sulfonmethane; and 22
1051	1051
1052	1052	(15) tiletamine and zolazepam or any salt thereof, including a 23
1053	1053	tiletamine–zolazepam combination product (trade name Telazol). 24
1054	1054
1055	1055	(d) As listed in Schedule III under Title 21 of the Code of Federal Regulations, 25
1056	1056	nalorphine 9400. 26
1057	1057
1058	1058	(e) Unless specifically excepted or unless listed in another schedule: 27
1059	1059
1060	1060	(1) substances listed in Schedule III include any material, compound, 28 SENATE BILL 189 23
1061	1061
1062	1062
1063	1063	mixture, or preparation containing any of the following narcotic drugs, or their salts 1
1064	1064	calculated as the free anhydrous base or alkaloid, in limited quantities as set forth below: 2
1065	1065
1066	1066	(i) not more than 1.80 grams of codeine per 100 milliliters or not 3
1067	1067	more than 90 milligrams per dosage unit, with an equal or greater quantity of an 4
1068	1068	isoquinoline alkaloid of opium; 5
1069	1069
1070	1070	(ii) not more than 1.80 grams of codeine per 100 milliliters or not 6
1071	1071	more than 90 milligrams per dosage unit, with one or more active, nonnarcotic ingredients 7
1072	1072	in recognized therapeutic amounts; 8
1073	1073
1074	1074	(iii) not more than 1.80 grams of dihydrocodeine per 100 milliliters 9
1075	1075	or not more than 90 milligrams per dosage unit, with one or more active, nonnarcotic 10
1076	1076	ingredients in recognized therapeutic amounts; 11
1077	1077
1078	1078	(iv) not more than 300 milligrams of ethylmorphine per 100 12
1079	1079	milliliters or not more than 15 milligrams per dosage unit, with one or more active, 13
1080	1080	nonnarcotic ingredients in recognized therapeutic amounts; 14
1081	1081
1082	1082	(v) not more than 500 milligrams of opium per 100 milliliters or per 15
1083	1083	100 grams, or not more than 25 milligrams per dosage unit, with one or more active, 16
1084	1084	nonnarcotic ingredients in recognized therapeutic amounts; 17
1085	1085
1086	1086	(vi) not more than 100 milligrams of opium per 100 milliliters or per 18
1087	1087	100 grams, or not more than 5 milligrams per dosage unit; and 19
1088	1088
1089	1089	(vii) not more than 50 milligrams of morphine per 100 milliliters or 20
1090	1090	per 100 grams with one or more active, nonnarcotic ingredients in recognized therapeutic 21
1091	1091	amounts. 22
1092	1092
1093	1093	(2) any material, compound, mixture, or preparation containing any of the 23
1094	1094	following narcotic drugs or their salts, as set forth below: 24
1095	1095
1096	1096	(i) buprenorphine; and 25
1097	1097
1098	1098	(ii) reserved. 26
1099	1099
1100	1100	(3) if not combined with one or more active medicinal ingredients that are 27
1101	1101	listed in another schedule, substances listed in Schedule III include a suppository dosage 28
1102	1102	form or salt of a suppository dosage that contains: 29
1103	1103
1104	1104	(i) amobarbital; 30
1105	1105
1106	1106	(ii) secobarbital; or 31
1107	1107
1108	1108	(iii) pentobarbital. 32
1109	1109	24 SENATE BILL 189
1110	1110
1111	1111
1112	1112	(f) (1) Except as provided in paragraph (2) of this subsection, an anabolic 1
1113	1113	steroid consisting of any material, compound, mixture, or preparation containing any 2
1114	1114	quantity of the following substances, including its salts, esters, and ethers: 3
1115	1115
1116	1116	(i) 3beta,17–dihydroxy–5a–androstane; 4
1117	1117
1118	1118	(ii) 3alpha,17beta–dihydroxy–5a–androstane; 5
1119	1119
1120	1120	(iii) 5 alpha–androstan–3,17–dione; 6
1121	1121
1122	1122	(iv) 1–androstenediol (3beta,17beta–dihydroxy–5alpha–androst–1 7
1123	1123	–ene); 8
1124	1124
1125	1125	(v) 1–androstenediol (3alpha,17beta–dihydroxy–5alpha–androst 9
1126	1126	–1–ene); 10
1127	1127
1128	1128	(vi) 4–androstenediol (3beta,17beta–dihydroxy–androst–4–ene); 11
1129	1129
1130	1130	(vii) 5–androstenediol (3beta,17beta–dihydroxy–androst–5–ene); 12
1131	1131
1132	1132	(viii) 1–androstenedione; 13
1133	1133
1134	1134	(ix) 4–androstenedione; 14
1135	1135
1136	1136	(x) 5–androstenedione; 15
1137	1137
1138	1138	(xi) bolasterone; 16
1139	1139
1140	1140	(xii) boldenone; 17
1141	1141
1142	1142	(xiii) boldione; 18
1143	1143
1144	1144	(xiv) calusterone; 19
1145	1145
1146	1146	(xv) chlorotestosterone (clostebol); 20
1147	1147
1148	1148	(xvi) dehydrochloromethyltestosterone; 21
1149	1149
1150	1150	(xvii) desoxymethyltestosterone; 22
1151	1151
1152	1152	(xviii) delta1–dihydrotestosterone (17beta–hydroxy–5alpha–androst 23
1153	1153	–1–en–3–one); 24
1154	1154
1155	1155	(xix) dihydrotestosterone (4–dihydrotestosterone) (17beta–hydroxy 25
1156	1156	– androstan–3–one) (stanolone); 26
1157	1157
1158	1158	(xx) drostanolone; 27 SENATE BILL 189 25
1159	1159
1160	1160
1161	1161
1162	1162	(xxi) ethylestrenol; 1
1163	1163
1164	1164	(xxii) fluoxymesterone; 2
1165	1165
1166	1166	(xxiii) formebolone; 3
1167	1167
1168	1168	(xxiv) furazabol; 4
1169	1169
1170	1170	(xxv) 13beta–ethyl–17beta–hydroxygon–4–en–3–one; 5
1171	1171
1172	1172	(xxvi) 4–hydroxytestosterone; 6
1173	1173
1174	1174	(xxvii) 4–hydroxy–19–nortestosterone; 7
1175	1175
1176	1176	(xxviii) mestanolone (17alpha –methyl–17beta–hydroxy–5 8
1177	1177	–androstan–3–one); 9
1178	1178
1179	1179	(xxix) mesterolone; 10
1180	1180
1181	1181	(xxx) methandienone (methandrostenolone) (17alpha –methyl 11
1182	1182	–17beta–hydroxyandrost–1,4–dien–3–one); 12
1183	1183
1184	1184	(xxxi) methandriol; 13
1185	1185
1186	1186	(xxxii) methasterone; 14
1187	1187
1188	1188	(xxxiii) methenolone; 15
1189	1189
1190	1190	(xxxiv) 17alpha–methyl–3beta, 17beta –dihydroxy–5a 16
1191	1191	–androstane; 17
1192	1192
1193	1193	(xxxv) 17alpha–methyl–3alpha, 17beta–dihydroxy–5a–androstane; 18
1194	1194
1195	1195	(xxxvi) 17alpha–methyl–3beta, 17beta–dihydroxyandrost–4–ene; 19
1196	1196
1197	1197	(xxxvii) 17alpha–methyl–4–hydroxynandrolone; 20
1198	1198
1199	1199	(xxxviii) methyldienolone; 21
1200	1200
1201	1201	(xxxix) methyltrienolone; 22
1202	1202
1203	1203	(xl) methyltestosterone; 23
1204	1204
1205	1205	(xli) mibolerone; 24
1206	1206
1207	1207	(xlii) 17alpha–methyl–delta1–dihydrotestosterone; 25 26 SENATE BILL 189
1208	1208
1209	1209
1210	1210
1211	1211	(xliii) nandrolone; 1
1212	1212
1213	1213	(xliv) 19–nor–4–androstenediol (3beta, 17beta–dihydroxyestr–4–ene); 2
1214	1214
1215	1215	(xlv) 19–nor–4–androstenediol (3alpha, 17beta–dihydroxyestr–4 3
1216	1216	–ene); 4
1217	1217
1218	1218	(xlvi) 19–nor–5–androstenediol (3beta, 17beta–dihydroxyestr–5–ene); 5
1219	1219
1220	1220	(xlvii) 19–nor–5–androstenediol (3alpha, 17beta–dihydroxyestr–5 6
1221	1221	–ene); 7
1222	1222
1223	1223	(xlviii) 19–nor–4,9(10)–androstadienedione; 8
1224	1224
1225	1225	(xlix) 19–nor–4–androstenedione; 9
1226	1226
1227	1227	(l) 19–nor–5–androstenedione; 10
1228	1228
1229	1229	(li) norbolethone (13beta, 17alpha–diethyl–17beta–hydroxygon–4 11
1230	1230	–en–3–one); 12
1231	1231
1232	1232	(lii) norclostebol; 13
1233	1233
1234	1234	(liii) norethandrolone; 14
1235	1235
1236	1236	(liv) normethandrolone; 15
1237	1237
1238	1238	(lv) oxandrolone; 16
1239	1239
1240	1240	(lvi) oxymesterone; 17
1241	1241
1242	1242	(lvii) oxymetholone; 18
1243	1243
1244	1244	(lviii) prostanozol; 19
1245	1245
1246	1246	(lix) stanozolol; 20
1247	1247
1248	1248	(lx) stenbolone; 21
1249	1249
1250	1250	(lxi) testolactone; 22
1251	1251
1252	1252	(lxii) testosterone; 23
1253	1253
1254	1254	(lxiii) tetrahydrogestrinone; and 24
1255	1255
1256	1256	(lxiv) trenbolone. 25 SENATE BILL 189 27
1257	1257
1258	1258
1259	1259
1260	1260	(2) The following substances are not included in Schedule III: 1
1261	1261
1262	1262	(i) an estrogen, progestin, [or] corticosteroid, OR 2
1263	1263	DEHYDROEPIANDROSTERO NE; or 3
1264	1264
1265	1265	(ii) a substance covered by paragraph (1) of this subsection if: 4
1266	1266
1267	1267	1. expressly intended for administration through implants to 5
1268	1268	cattle or other nonhuman species; and 6
1269	1269
1270	1270	2. approved for that use by the U.S. Food and Drug 7
1271	1271	Administration. 8
1272	1272
1273	1273	(g) Hallucinogenic substances include: 9
1274	1274
1275	1275	(1) dronabinol (synthetic) in sesame oil and encapsulated in a soft gelatin 10
1276	1276	capsule in a U.S. Food and Drug Administration–approved product; and 11
1277	1277
1278	1278	(2) reserved. 12
1279	1279
1280	1280	(h) The Department may not add a substance to Schedule III under § 5–202 of 13
1281	1281	this title unless the Department finds: 14
1282	1282
1283	1283	(1) a potential for abuse of the substance that is less than that for the 15
1284	1284	substances listed in Schedule I and Schedule II; 16
1285	1285
1286	1286	(2) well documented and approved medical use of the substance in the 17
1287	1287	United States; and 18
1288	1288
1289	1289	(3) evidence that abuse of the substance may lead to moderate or low 19
1290	1290	physical dependence or high psychological dependence. 20
1291	1291
1292	1292	5–405. 21
1293	1293
1294	1294	(a) Schedule IV consists of each controlled dangerous substance: 22
1295	1295
1296	1296	(1) listed in this section; 23
1297	1297
1298	1298	(2) added to Schedule IV by the Department under § 5–202(b) of this title; 24
1299	1299	or 25
1300	1300
1301	1301	(3) designated as a Schedule IV controlled dangerous substance by the 26
1302	1302	federal government unless the Department objects under § 5–202(f) of this title. 27
1303	1303
1304	1304	(b) Unless specifically excepted or unless listed in another schedule, any material, 28
1305	1305	compound, mixture, or preparation containing any of the following narcotic drugs, or their 29 28 SENATE BILL 189
1306	1306
1307	1307
1308	1308	salts calculated as the free anhydrous base or alkaloid, in limited quantities as set forth 1
1309	1309	below: 2
1310	1310
1311	1311	(1) not more than 1 milligram of difenoxin and not less than 25 micrograms 3
1312	1312	of atropine sulfate per dosage unit; 4
1313	1313
1314	1314	(2) dextropropoxyphene (alpha–(+)–4–dimethylamino–1, 2–diphenyl–3 5
1315	1315	– methyl–2–propionoxybutane); and 6
1316	1316
1317	1317	(3) 2–[(dimethylamino)methyl]–1–(3–methoxyphenyl)cyclohexanol, its 7
1318	1318	salts, optical and geometric isomers and salts of these isomers (including tramadol). 8
1319	1319
1320	1320	(c) Substances listed in Schedule IV include a material, compound, mixture, or 9
1321	1321	preparation that contains any quantity of the following substances having a potential for 10
1322	1322	abuse associated with a depressant effect on the central nervous system, including its salts, 11
1323	1323	isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of 12
1324	1324	isomers is possible within the specific chemical designations: 13
1325	1325
1326	1326	(1) alfaxalone; 14
1327	1327
1328	1328	(2) alprazolam; 15
1329	1329
1330	1330	(3) barbital; 16
1331	1331
1332	1332	(4) brexanolone; 17
1333	1333
1334	1334	(5) bromazepam; 18
1335	1335
1336	1336	(6) camazepam; 19
1337	1337
1338	1338	(7) carisoprodol; 20
1339	1339
1340	1340	(8) chloral betaine; 21
1341	1341
1342	1342	(9) chloral hydrate; 22
1343	1343
1344	1344	(10) chlordiazepoxide; 23
1345	1345
1346	1346	(11) clobazam; 24
1347	1347
1348	1348	(12) clonazepam; 25
1349	1349
1350	1350	(13) clorazepate; 26
1351	1351
1352	1352	(14) clotiazepam; 27
1353	1353
1354	1354	(15) cloxazolam; 28 SENATE BILL 189 29
1355	1355
1356	1356
1357	1357
1358	1358	(16) delorazepam; 1
1359	1359
1360	1360	(17) diazepam; 2
1361	1361
1362	1362	(18) dichloralphenazone; 3
1363	1363
1364	1364	(19) estazolam; 4
1365	1365
1366	1366	(20) ethchlorvynol; 5
1367	1367
1368	1368	(21) ethinamate; 6
1369	1369
1370	1370	(22) ethyl loflazepate; 7
1371	1371
1372	1372	(23) fludiazepam; 8
1373	1373
1374	1374	(24) flunitrazepam; 9
1375	1375
1376	1376	(25) flurazepam; 10
1377	1377
1378	1378	(26) fospropofol; 11
1379	1379
1380	1380	(27) halazepam; 12
1381	1381
1382	1382	(28) haloxazolam; 13
1383	1383
1384	1384	(29) ketazolam; 14
1385	1385
1386	1386	(30) LEMBOREXANT ; 15
1387	1387
1388	1388	(31) loprazolam; 16
1389	1389
1390	1390	[(31)] (32) lorazepam; 17
1391	1391
1392	1392	[(32)] (33) lormetazepam; 18
1393	1393
1394	1394	[(33)] (34) mebutamate; 19
1395	1395
1396	1396	[(34)] (35) medazepam; 20
1397	1397
1398	1398	[(35)] (36) meprobamate; 21
1399	1399
1400	1400	[(36)] (37) methohexital; 22
1401	1401
1402	1402	[(37)] (38) methylphenobarbital (mephobarbital); 23 30 SENATE BILL 189
1403	1403
1404	1404
1405	1405
1406	1406	[(38)] (39) midazolam; 1
1407	1407
1408	1408	[(39)] (40) nimetazepam; 2
1409	1409
1410	1410	[(40)] (41) nitrazepam; 3
1411	1411
1412	1412	[(41)] (42) nordiazepam; 4
1413	1413
1414	1414	[(42)] (43) oxazepam; 5
1415	1415
1416	1416	[(43)] (44) oxazolam; 6
1417	1417
1418	1418	[(44)] (45) paraldehyde; 7
1419	1419
1420	1420	[(45)] (46) petrichloral; 8
1421	1421
1422	1422	[(46)] (47) phenobarbital; 9
1423	1423
1424	1424	[(47)] (48) pinazepam; 10
1425	1425
1426	1426	[(48)] (49) prazepam; 11
1427	1427
1428	1428	[(49)] (50) quazepam; 12
1429	1429
1430	1430	(51) REMIMAZOLAM ; 13
1431	1431
1432	1432	[(50)] (52) suvorexant (Belsomra); 14
1433	1433
1434	1434	[(51)] (53) temazepam; 15
1435	1435
1436	1436	[(52)] (54) tetrazepam; 16
1437	1437
1438	1438	[(53)] (55) triazolam; 17
1439	1439
1440	1440	[(54)] (56) zaleplon (Sonata); 18
1441	1441
1442	1442	[(55)] (57) zolpidem (Ambien); and 19
1443	1443
1444	1444	[(56)] (58) zopiclone (Lunesta). 20
1445	1445
1446	1446	(d) Substances listed in Schedule IV include: 21
1447	1447
1448	1448	(1) a material, compound, mixture, or preparation that contains 22
1449	1449	fenfluramine; and 23 SENATE BILL 189 31
1450	1450
1451	1451
1452	1452
1453	1453	(2) if its existence is possible: 1
1454	1454
1455	1455	(i) a salt of fenfluramine; 2
1456	1456
1457	1457	(ii) an optical, position, or geometric isomer of fenfluramine, 3
1458	1458	including dexfenfluramine; and 4
1459	1459
1460	1460	(iii) a salt of an isomer of fenfluramine. 5
1461	1461
1462	1462	(e) Substances listed in Schedule IV include: 6
1463	1463
1464	1464	(1) a material, compound, mixture, or preparation that contains lorcaserin; 7
1465	1465	and 8
1466	1466
1467	1467	(2) if its existence is possible: 9
1468	1468
1469	1469	(i) a salt of lorcaserin; 10
1470	1470
1471	1471	(ii) an optical, position, or geometric isomer of lorcaserin; and 11
1472	1472
1473	1473	(iii) a salt of an isomer of lorcaserin. 12
1474	1474
1475	1475	(f) Substances listed in Schedule IV include a material, compound, mixture, or 13
1476	1476	preparation that contains any quantity of the following substances having a potential for 14
1477	1477	abuse associated with a stimulant effect on the central nervous system, including its salts, 15
1478	1478	isomers, and salts of isomers: 16
1479	1479
1480	1480	(1) cathine ((+)–norpseudoephedrine); 17
1481	1481
1482	1482	(2) diethylpropion; 18
1483	1483
1484	1484	(3) fencamfamin; 19
1485	1485
1486	1486	(4) fenproporex; 20
1487	1487
1488	1488	(5) mazindol; 21
1489	1489
1490	1490	(6) mefenorex; 22
1491	1491
1492	1492	(7) modafinil; 23
1493	1493
1494	1494	(8) pemoline, including organometallic complexes and their chelates; 24
1495	1495
1496	1496	(9) phentermine; 25
1497	1497
1498	1498	(10) pipradrol; 26 32 SENATE BILL 189
1499	1499
1500	1500
1501	1501
1502	1502	(11) SERDEXMETHYLPHENIDAT E; 1
1503	1503
1504	1504	(12) sibutramine; 2
1505	1505
1506	1506	[(12)] (13) solriamfetol (2 –amino–3–phenylpropyl carbamate; 3
1507	1507	benzenepropanol, beta–amino–, carbamate (ester)); and 4
1508	1508
1509	1509	[(13)] (14) SPA ((–)–1–dimethylamino–1,2–diphenylethane). 5
1510	1510
1511	1511	(g) Unless specifically excepted or unless listed in another schedule, any material, 6
1512	1512	compound, mixture, or preparation that contains any quantity of the following substances, 7
1513	1513	including its salts: 8
1514	1514
1515	1515	(1) pentazocine; 9
1516	1516
1517	1517	(2) butorphanol (including its optical isomers); and 10
1518	1518
1519	1519	(3) eluxadoline (5 –[[[(2S)–2–amino–3–[4–aminocarbonyl)–2, 11
1520	1520	6– dimethylphenyl]–1–oxopropyl][(1S)–1–(4–phenyl–1H–imidazol–2– 12
1521	1521	yl)ethyl]amino]methyl]–2–methoxybenzoic acid) (including its optical isomers) and its 13
1522	1522	salts, isomers, and salts of isomers. 14
1523	1523
1524	1524	(h) By regulation, the Department may exempt from this section a compound, 15
1525	1525	mixture, or preparation that contains a depressant substance listed in subsection (c) of this 16
1526	1526	section if: 17
1527	1527
1528	1528	(1) the compound, mixture, or preparation contains an active medicinal 18
1529	1529	ingredient that does not have a depressant effect on the central nervous system; and 19
1530	1530
1531	1531	(2) the admixtures are included in combinations, quantity, proportion, or 20
1532	1532	concentration that vitiate the potential for abuse of the substances that have a depressant 21
1533	1533	effect on the central nervous system. 22
1534	1534
1535	1535	(i) The Department may not add a substance to Schedule IV under § 5–202 of 23
1536	1536	this title unless the Department finds that: 24
1537	1537
1538	1538	(1) the substance has a low potential for abuse relative to the substances 25
1539	1539	listed in Schedule III; 26
1540	1540
1541	1541	(2) the substance has currently accepted medical use in treatment in the 27
1542	1542	United States; and 28
1543	1543
1544	1544	(3) abuse of the substance may lead to limited physical dependence or 29
1545	1545	psychological dependence relative to the substances in Schedule III. 30
1546	1546
1547	1547	5–406. 31 SENATE BILL 189 33
1548	1548
1549	1549
1550	1550
1551	1551	(a) Schedule V consists of each controlled dangerous substance: 1
1552	1552
1553	1553	(1) listed in this section; 2
1554	1554
1555	1555	(2) added to Schedule V by the Department under § 5–202(b) of this title; 3
1556	1556	or 4
1557	1557
1558	1558	(3) designated as a Schedule V controlled dangerous substance by the 5
1559	1559	federal government unless the Department objects under § 5–202(f) of this title. 6
1560	1560
1561	1561	(b) Unless specifically excepted or unless listed in another schedule, any material, 7
1562	1562	compound, mixture, or preparation containing any of the following narcotic drugs and their 8
1563	1563	salts, as set forth below: 9
1564	1564
1565	1565	(1) reserved; and 10
1566	1566
1567	1567	(2) reserved. 11
1568	1568
1569	1569	(c) Any compound, mixture, or preparation containing any of the following 12
1570	1570	narcotic drugs, or their salts calculated as the free anhydrous base or alkaloid, in limited 13
1571	1571	quantities as set forth below, which shall include one or more nonnarcotic active medicinal 14
1572	1572	ingredients in sufficient proportion to confer upon the compound, mixture, or preparation 15
1573	1573	valuable medicinal qualities other than those possessed by narcotic drugs alone: 16
1574	1574
1575	1575	(1) not more than 200 milligrams of codeine per 100 milliliters or per 100 17
1576	1576	grams; 18
1577	1577
1578	1578	(2) not more than 100 milligrams of dihydrocodeine per 100 milliliters or 19
1579	1579	per 100 grams; 20
1580	1580
1581	1581	(3) not more than 100 milligrams of ethylmorphine per 100 milliliters or 21
1582	1582	per 100 grams; 22
1583	1583
1584	1584	(4) not more than 2.5 milligrams of diphenoxylate and not less than 25 23
1585	1585	micrograms of atropine sulfate per dosage unit; or 24
1586	1586
1587	1587	(5) NOT MORE THAN 0.5 MILLIGRAM OF DIFENOX IN AND NOT LESS 25
1588	1588	THAN 25 MICROGRAMS OF ATROPI NE SULFATE PER DOSAG E UNIT (difenoxin 26
1589	1589	preparations 0.5mg/25ug ATSO4/DU (MOTOFEN) ). 27
1590	1590
1591	1591	(d) Unless specifically exempted or excluded or unless listed in another schedule, 28
1592	1592	any material, compound, mixture, or preparation that contains any quantity of the 29
1593	1593	following substances having a stimulant effect on the central nervous system, including its 30
1594	1594	salts, isomers, and salts of isomers: 31
1595	1595
1596	1596	(1) pyrovalerone; and 32 34 SENATE BILL 189
1597	1597
1598	1598
1599	1599
1600	1600	(2) reserved. 1
1601	1601
1602	1602	(e) Unless specifically exempted or excluded or unless listed in another schedule, 2
1603	1603	any material, compound, mixture, or preparation that contains any quantity of the 3
1604	1604	following substances having a depressant effect on the central nervous system, including 4
1605	1605	its salts: 5
1606	1606
1607	1607	(1) brivaracetam ((2S) –2–[(4R)–2–oxo–4–propylpyrrolidin–1–yl] 6
1608	1608	butanamide) (Briviact); 7
1609	1609
1610	1610	(2) CENOBAMATE ([(1R)–1–(2–CHLOROPHENYL )–2–(TETRAZOL–2 8
1611	1611	–YL)ETHYL] CARBAMATE ; 2H–TETRAZOLE–2–ETHANOL, ALPHA–(2 9
1612	1612	–CHLOROPHENYL )–, CARBAMATE (ESTER), (ALPHAR)–; CARBAMIC ACID (R)–(+)–1 10
1613	1613	–(2–CHLOROPHENYL )–2–(2H–TETRAZOL–2–YL)ETHYL ESTER); 11
1614	1614
1615	1615	(3) ezogabine [N–[2–amino–4–(4–fluorobenzylamino)–phenyl] 12
1616	1616	–carbamic acid ethyl ester] (Potiga); 13
1617	1617
1618	1618	[(3)] (4) lacosamide [(R) –2–acetoamido–N–benzyl–3–methoxy 14
1619	1619	–propionamide] (Vimpat); [and] 15
1620	1620
1621	1621	(5) LASMIDITAN [2,4,6–TRIFLUORO–N–(6–(1–METHYLPIPERIDINE 16
1622	1622	–4–CARBONYL)PYRIDINE–2–YL–BENZAMIDE]; AND 17
1623	1623
1624	1624	[(4)] (6) pregabalin [(S)–3–(aminomethyl)–5–methylhexanoic acid] 18
1625	1625	(Lyrica). 19
1626	1626
1627	1627	[(f) A drug product in finished dosage formulation that has been approved by the 20
1628	1628	United States Food and Drug Administration that contains cannabidiol (2–[1R–3–methyl 21
1629	1629	–6R–(1–methylethenyl)–2–cyclohexen–1–yl]–5–pentyl–1,3–benzenediol) derived from 22
1630	1630	cannabis and no more than 0.1% (w/w) residual tetrahydrocannabinols.] 23
1631	1631
1632	1632	[(g)] (F) The Department may not add a substance to Schedule V under § 5–202 24
1633	1633	of this title unless the Department finds: 25
1634	1634
1635	1635	(1) the substance has a low potential for abuse relative to the substances 26
1636	1636	listed in Schedule IV; 27
1637	1637
1638	1638	(2) the substance has currently accepted medical use in the United States; 28
1639	1639	and 29
1640	1640
1641	1641	(3) abuse of the substance may lead to limited physical dependence or 30
1642	1642	psychological dependence liability relative to the substances listed in Schedule IV. 31
1643	1643
1644	1644	SECTION 2. AND BE IT FURTHER ENACTED, That this Act shall take effect 32 SENATE BILL 189 35
1645	1645
1646	1646
1647	1647	October 1, 2022. 1